Allergic reactions to brimonidine in patients treated for glaucoma

Canadian Journal of Ophthalmology

Volumn 37, Issue 1, 2002, Pages 21-26

  Blondeau, Pierre ^a   Rousseau, Jacques Armand ^a  

^a UNIVERSITÉ DE SHERBROOKE   (Canada)

Author keywords

Adrenergic agonists; Allergic contact; Dermatitis; Glaucoma; Hypersensitivity

Indexed keywords

ACETAZOLAMIDE; ADRENALIN; ANTIGLAUCOMA AGENT; BETAXOLOL; BRIMONIDINE; DIPIVEFRINE; DORZOLAMIDE; LATANOPROST; LEVOBUNOLOL; PILOCARPINE; TIMOLOL;

ADULT; AGED; ALLERGIC CONJUNCTIVITIS; ALLERGIC REACTION; ARTICLE; CONTROLLED STUDY; DRUG HYPERSENSITIVITY; FEMALE; GLAUCOMA; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; RISK FACTOR;

EID: 0036198376     PISSN: 00084182     EISSN: 17153360     Source Type: Journal    
DOI: 10.1016/S0008-4182(02)80094-1     Document Type: Article

References (22)

1. A comparison of the safety and efficacy of twice daily brimonidine 0.2% versus betaxolol 0.25% in subjects with elevated intraocular pressure
2. Clinical experience with brimonidine 0.2% and timolol 0.5% in glaucoma and ocular hypertension
3. A 1-year study of brimonidine twice daily in glaucoma and ocular hypertension. A controlled, randomized, multicenter clinical trial
4. Twelve-month results of an ongoing randomized trial comparing brimonidine tartrate 0.2% and timolol 0.5% given twice daily in patients with glaucoma or ocular hypertension
5. Brimonidine tartrate 0.2% twice daily vs timolol 0.5% twice daily: 1-Year results in glaucoma patients
6. Efficacy of brimonidine 0.2% as adjunctive therapy for patients with glaucoma inadequately controlled with otherwise maximal medical therapy
7. Ongoing clinical assessment of the safety profile and efficacy of brimonidine compared with timolol: Year-three results
8. A retrospective examination of drug-induced allergy to Alphagan and a proposal for a new reporting system
9. Comparison of apraclonidine and timolol in chronic open-angle glaucoma. A three-month study
10. Long term effect of apraclonidine
11. The efficacy of apraclonidine as an adjunct to timolol therapy
12. Clinical experience with the long-term use of 1% apraclonidine. Incidence of allergic reactions
13. Long-term brimonidine therapy in glaucoma patients with apraclonidine allergy
14. Lack of cross-reactive allergic response to brimonidine in patient with known apraclonidine allergy
15. Incidence of brimonidine allergy in patients previously allergic to apraclonidine
16. Antiglaucoma medications: A review of safety and tolerability issues related to their use
17. Contact allergy, irritancy and "danger
18. Thresholds in contact sensitization: Theoretical and practical considerations
19. Adverse external ocular effects of topical ophthalmic medications
20. Allergic contact sensitivity to benzalkonium chloride. Cutaneous, ophthalmic and general medical implications
21. Mechanisms of adrenergic agonist induced allergy bioactivation and antigen formation